• Corpus ID: 221446047

Computational screening of repurposed drugs and natural products against SARS-Cov-2 main protease (Mpro) as potential COVID-19 therapies

@article{Piplani2020ComputationalSO,
  title={Computational screening of repurposed drugs and natural products against SARS-Cov-2 main protease (Mpro) as potential COVID-19 therapies},
  author={Sakshi Piplani and Puneet Kumar Singh and Nikolai Petrovsky and David A. Winkler},
  journal={arXiv: Biomolecules},
  year={2020}
}
There remains an urgent need to identify existing drugs that might be suitable for treating patients suffering from COVID-19 infection. Drugs rarely act at a single molecular target, with off target effects often being responsible for undesirable side effects and sometimes, beneficial synergy between targets for a specific illness. Off target activities have also led to blockbuster drugs in some cases, e.g. Viagra for erectile dysfunction and Minoxidil for male pattern hair loss. Drugs already… 

Figures and Tables from this paper

Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies

TLDR
The modelling approach successfully identified multiple drugs with potential activity against SARS-CoV-2 RdRp, and these top hits may not only have utility in treating COVID-19 but may provide a useful starting point for therapeutics against other coronaviruses.

Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase

TLDR
A virtual screening approach using Autodock Vina and molecular dynamic simulation in tandem to screen and calculate binding energies of repurposed drugs against the SARS-CoV-2 helicase protein (non-structural protein nsp13).

Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns

TLDR
A literature review of large-scale SARS-CoV-2 antiviral drug repurposing efforts is provided and a marked lack of consistent potency reporting is highlighted, indicating the importance of standardizing best practices.

References

SHOWING 1-10 OF 89 REFERENCES

Repurposing drugs for treatment of SARS-CoV-2 infection: computational design insights into mechanisms of action

TLDR
The results from this study may help to accelerate drug development against COVID-19 and the hit compounds should be progressed through further in vitro and in vivo studies on SARS-CoV-2.

Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of COVID-19 Main Protease: A Virtual Drug Repurposing Study

TLDR
A physics-driven high throughput virtual screening drug re-purposing approach to identify new compounds against COVID-19, one of the most attractive targets for the development of new drugs against this virus due to its pivotal role in the replication and transcription of the virus.

Drug Repurposing and New Therapeutic Strategies for SARS-CoV-2 Disease Using a Novel Molecular Modeling-AI Hybrid Workflow

TLDR
This work tasked its novel molecular modeling-AI hybrid computational platform with finding potential inhibitors of the SARS-CoV-2 main protease (Mpro, 3CLpro), which resulted in the identification of several promising molecules.

Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.

TLDR
This work opens a new avenue of research to probe into the molecular mechanism of action of many drugs, which are known to demonstrate anti-viral activity but are so far not known to target viral proteases.

Prioritization of Potential Drugs Targeting the SARS-CoV-2 Main Protease

TLDR
A computational approach to prioritize potential inhibitors that directly target the core enzyme of SARS-Cov-2, the main protease, which is responsible for processing the viral RNA-translated polyprotein into functional proteins for viral replication reveals intriguing molecular patterns that are worth future explorations.

Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2

TLDR
There are an urgent need for antivirals to treat the newly emerged SARS-CoV-2 and a repurposing library of ~3,000 drugs was screened, finding 9 drugs are antiviral in lung cells, 7 of which have been tested in humans, and 3 are FDA approved including Cyclosporine.

Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking Screening.

TLDR
Virtual screening and molecular docking methods suggest the effectiveness of Beclabuvir, Nilotinib, Tirilazad, Trametinib and Glecaprevir as potent drugs against SARS-CoV-2 since they tightly bind to its main protease.

Drug Repurposing Approach Targeted Against Main Protease of SARS-CoV-2 Exploiting ‘Neighbourhood Behaviour’ in 3D Protein Structural Space and 2D Chemical Space of Small Molecules

TLDR
The preliminary analysis of the available data on the deadly pathogen SARS-CoV-2 suggested more than 20 known drugs/drug candidates which might elucidate anti-coronavirus properties by binding to main protease of the pathogen.

Identification of Potent COVID-19 Main Protease (Mpro) Inhibitors from Natural Polyphenols: An in Silico Strategy Unveils a Hope against CORONA

COVID-19, a rapidly spreading new strain of coronavirus, has affected more than 150 countries and received worldwide attention. The lack of efficacious drugs or vaccines against SARS-CoV-2 has
...